X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (248) 248
index medicus (240) 240
lisdexamfetamine dimesylate (235) 235
attention deficit disorder with hyperactivity - drug therapy (174) 174
double-blind (166) 166
psychiatry (158) 158
male (138) 138
attention-deficit/hyperactivity disorder (130) 130
pharmacology & pharmacy (128) 128
female (127) 127
adhd (122) 122
central nervous system stimulants - therapeutic use (122) 122
attention-deficit hyperactivity disorder (105) 105
adult (104) 104
central nervous system stimulants - adverse effects (104) 104
deficit hyperactivity disorder (101) 101
treatment outcome (101) 101
attention deficit hyperactivity disorder (97) 97
children (97) 97
child (96) 96
methylphenidate (95) 95
adolescent (94) 94
dextroamphetamine - therapeutic use (90) 90
drug therapy (86) 86
dextroamphetamine - adverse effects (81) 81
efficacy (81) 81
safety (76) 76
double-blind method (71) 71
lisdexamfetamine (65) 65
central nervous system stimulants - administration & dosage (64) 64
clinical neurology (60) 60
pharmacotherapy (59) 59
adults (58) 58
adolescents (56) 56
dose-response relationship, drug (56) 56
medicine & public health (54) 54
dextroamphetamine - administration & dosage (53) 53
neurosciences (50) 50
amphetamine (49) 49
middle aged (47) 47
pediatrics (45) 45
psychopharmacology (43) 43
research (43) 43
young adult (43) 43
lisdexamfetamine dimesylate - therapeutic use (42) 42
stimulants (42) 42
hyperactivity (41) 41
open-label (41) 41
care and treatment (40) 40
methylphenidate - therapeutic use (39) 39
atomoxetine (38) 38
placebo-controlled trial (38) 38
attention deficit disorder with hyperactivity - psychology (37) 37
analysis (36) 36
salts extended-release (36) 36
clinical trials (35) 35
teenagers (34) 34
extended-release (33) 33
dosage and administration (32) 32
neurology (32) 32
amphetamines (31) 31
oros methylphenidate (31) 31
medicine, general & internal (30) 30
pharmacokinetics (30) 30
psychology, developmental (30) 30
lisdexamfetamine dimesylate - adverse effects (29) 29
pharmacology (29) 29
deficit/hyperactivity disorder (28) 28
original (28) 28
psychiatric status rating scales (28) 28
studies (28) 28
dimesylate (27) 27
internal medicine (27) 27
methylphenidate - adverse effects (26) 26
stimulant (26) 26
mixed amphetamine salts (25) 25
atomoxetine hydrochloride (24) 24
comorbidity (23) 23
hyperactivity disorder (23) 23
mental disorders (23) 23
psychiatry and mental health (23) 23
randomized controlled trials as topic (23) 23
attention deficit disorder with hyperactivity - diagnosis (22) 22
children & youth (22) 22
controlled-trial (22) 22
cross-over studies (22) 22
deficit-hyperactivity disorder (22) 22
health aspects (22) 22
attention-deficit (21) 21
central nervous system stimulants - pharmacology (21) 21
dextroamphetamine - pharmacokinetics (21) 21
dextroamphetamine - pharmacology (21) 21
drug administration schedule (21) 21
quality-of-life (21) 21
amphetamines - therapeutic use (20) 20
binge-eating disorder - drug therapy (20) 20
prevalence (20) 20
abridged index medicus (19) 19
drugs (19) 19
attention deficit disorder with hyperactivity - physiopathology (18) 18
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of the American Academy of Child & Adolescent Psychiatry, ISSN 0890-8567, 2011, Volume 50, Issue 4, pp. 395 - 405
Journal Article
European Neuropsychopharmacology, ISSN 0924-977X, 2012, Volume 23, Issue 10, pp. 1208 - 1218
Abstract This study evaluated the efficacy and safety of lisdexamfetamine dimesylate (LDX) compared with placebo in children and adolescents with... 
Internal Medicine | Psychiatry | Attention deficit disorder with hyperactivity | Lisdexamfetamine dimesylate | Prodrugs | Central nervous system stimulants | Child | Adolescent | ADHD | EFFICACY | SAFETY | PSYCHIATRY | DEFICIT HYPERACTIVITY DISORDER | ADULTS | NEUROSCIENCES | CLINICAL NEUROLOGY | GUIDELINE | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | CROSSOVER | D-AMPHETAMINE | Attention Deficit Disorder with Hyperactivity - physiopathology | Impulsive Behavior - etiology | Follow-Up Studies | Impulsive Behavior - prevention & control | Humans | Dextroamphetamine - therapeutic use | Male | Patient Dropouts | Dextroamphetamine - adverse effects | Dose-Response Relationship, Drug | Psychiatric Status Rating Scales | Central Nervous System Stimulants - therapeutic use | Lisdexamfetamine Dimesylate | Central Nervous System Stimulants - adverse effects | Female | Child Behavior - drug effects | Drug Resistance | Methylphenidate - chemistry | Severity of Illness Index | Methylphenidate - administration & dosage | Diagnostic and Statistical Manual of Mental Disorders | Double-Blind Method | Europe | Appetite Regulation - drug effects | Methylphenidate - adverse effects | Adolescent Behavior - drug effects | Attention Deficit Disorder with Hyperactivity - drug therapy | Methylphenidate - therapeutic use | Central Nervous System Stimulants - administration & dosage | Dextroamphetamine - administration & dosage | Medicine, Experimental | Medical research | Adolescence
Journal Article
Neuropsychopharmacology, ISSN 0893-133X, 04/2016, Volume 41, Issue 5, pp. 1251 - 1260
The efficacy and safety of lisdexamfetamine dimesylate (LDX) vs placebo in binge eating disorder (BED) was evaluated in two multicenter, double-blind,... 
ORLISTAT | EFFICACY | SAFETY | PSYCHIATRY | TOPIRAMATE | NEUROSCIENCES | ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | OBESE-PATIENTS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | AMPHETAMINE | SIBUTRAMINE | Original
Journal Article
Drugs, ISSN 0012-6667, 07/2018, Volume 78, Issue 10, pp. 1025 - 1036
Lisdexamfetamine dimesylate (lisdexamfetamine; Elvanse (R); Tyvense (R)), an orally-active dexamfetamine prodrug, is indicated in the EU for the treatment of... 
PHARMACOLOGICAL-TREATMENT | ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | LONG-ACTING STIMULANTS | DEFICIT HYPERACTIVITY DISORDER | FUNCTIONAL OUTCOMES | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | GUANFACINE EXTENDED-RELEASE | TOXICOLOGY | QUALITY-OF-LIFE | HEAD-TO-HEAD | RANDOMIZED-WITHDRAWAL | Dextroamphetamine - pharmacology | Drug Administration Schedule | Europe | Humans | Dextroamphetamine - therapeutic use | Methylphenidate - pharmacology | Treatment Outcome | Drug Approval | Attention Deficit Disorder with Hyperactivity - drug therapy | Lisdexamfetamine Dimesylate - pharmacokinetics | Dose-Response Relationship, Drug | Central Nervous System Stimulants - therapeutic use | Central Nervous System Stimulants - adverse effects | Central Nervous System Stimulants - pharmacokinetics | Lisdexamfetamine Dimesylate - adverse effects | Methylphenidate - therapeutic use | Quality of Life | Lisdexamfetamine Dimesylate - therapeutic use | Central Nervous System Stimulants - administration & dosage | Child | Lisdexamfetamine Dimesylate - administration & dosage | Urine | Appetite | Headache | Hyperactivity | Attention deficit hyperactivity disorder | Pharmacology | Quality of life | Children & youth | Studies | Sleep disorders | Stimulants | Metabolites | Insomnia | Weight reduction | Teenagers | Children | Adolescents | Drug therapy | Psychiatry | Methylphenidate
Journal Article
Neuropsychopharmacology, ISSN 0893-133X, 2014, Volume 39, Issue 6, pp. 1388 - 1398
Journal Article
Journal Article
Journal Article
Journal Article